Zisková marža spoločnosti Lyxor Japan (Topix) (Dr) Ucits

Aká je hodnota metriky Zisková marža spoločnosti Lyxor Japan (Topix) (Dr) Ucits?

Hodnota metriky Zisková marža spoločnosti Lyxor Japan (Topix) (Dr) Ucits je 0.00%

Aká je definícia metriky Zisková marža?

Zisková marža (Profit margin) je percento čistého zisku z celkových tržieb.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Čomu sa venuje spoločnosť Lyxor Japan (Topix) (Dr) Ucits?

Lyxor UCITS ETF Japan (TOPIX) is an exchange traded fund launched and managed by Lyxor International Asset Management S.A. It invests in the public equity markets of Japan. The fund uses derivatives such as swap agreements to invest in the stocks of companies operating across diversified sectors. It invests in the stocks of large-cap companies. The fund seeks to replicate the performance of the TOPIX Gross Total Return Index, by employing synthetic replication methodology. It was formerly known as Lyxor ETF Japan (TOPIX). Lyxor UCITS ETF Japan (TOPIX) was formed on October 28, 2005 and is domiciled in France.

Firmy s metrikou zisková marža podobnou spoločnosti Lyxor Japan (Topix) (Dr) Ucits